154 related articles for article (PubMed ID: 26891801)
1. E2F1 promotes tumor cell invasion and migration through regulating CD147 in prostate cancer.
Liang YX; Lu JM; Mo RJ; He HC; Xie J; Jiang FN; Lin ZY; Chen YR; Wu YD; Luo HW; Luo Z; Zhong WD
Int J Oncol; 2016 Apr; 48(4):1650-8. PubMed ID: 26891801
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of PDZ-binding kinase confers malignant phenotype in prostate cancer via the regulation of E2F1.
Chen JH; Liang YX; He HC; Chen JY; Lu JM; Chen G; Lin ZY; Fu X; Ling XH; Han ZD; Jiang FN; Zhong WD
Int J Biol Macromol; 2015 Nov; 81():615-23. PubMed ID: 26314905
[TBL] [Abstract][Full Text] [Related]
3. [Effect of transcription factor E2F1 expression on the invasion of prostate cancer].
Bi XC; Pu XY; Liu JM; Huang S
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(36):2856-2859. PubMed ID: 29050152
[No Abstract] [Full Text] [Related]
4. Transcription factor p53-mediated activation of miR-519d-3p and downregulation of E2F1 attenuates prostate cancer growth and metastasis.
Zhang D; Yang XJ; Luo QD; Xue L; Chong T
Cancer Gene Ther; 2022 Jul; 29(7):1001-1011. PubMed ID: 34799723
[TBL] [Abstract][Full Text] [Related]
5. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD147 is associated with prostate cancer progression.
Zhong WD; Liang YX; Lin SX; Li L; He HC; Bi XC; Han ZD; Dai QS; Ye YK; Chen QB; Wang YS; Zeng GH; Zhu G; Zhang Z; Chen ZN; Wu CL
Int J Cancer; 2012 Jan; 130(2):300-8. PubMed ID: 21328337
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of CD147 promotes cell invasion, epithelial-to-mesenchymal transition and activates MAPK/ERK signaling pathway in colorectal cancer.
Xu T; Zhou M; Peng L; Kong S; Miao R; Shi Y; Sheng H; Li L
Int J Clin Exp Pathol; 2014; 7(11):7432-41. PubMed ID: 25550778
[TBL] [Abstract][Full Text] [Related]
8. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
9. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN
Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494
[TBL] [Abstract][Full Text] [Related]
10. Autophagy induced by overexpression of DCTPP1 promotes tumor progression and predicts poor clinical outcome in prostate cancer.
Lu J; Dong W; He H; Han Z; Zhuo Y; Mo R; Liang Y; Zhu J; Li R; Qu H; Zhang L; Wang S; Ma R; Jia Z; Zhong W
Int J Biol Macromol; 2018 Oct; 118(Pt A):599-609. PubMed ID: 29874556
[TBL] [Abstract][Full Text] [Related]
11. hnRNPM, a potential mediator of YY1 in promoting the epithelial-mesenchymal transition of prostate cancer cells.
Yang T; An Z; Zhang C; Wang Z; Wang X; Liu Y; Du E; Liu R; Zhang Z; Xu Y
Prostate; 2019 Aug; 79(11):1199-1210. PubMed ID: 31251827
[TBL] [Abstract][Full Text] [Related]
12. ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells.
Wang L; Li Y; Yang X; Yuan H; Li X; Qi M; Chang YW; Wang C; Fu W; Yang M; Zhang J; Han B
Prostate; 2014 May; 74(6):647-58. PubMed ID: 24435928
[TBL] [Abstract][Full Text] [Related]
13. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
14. Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells.
Ren D; Wang M; Guo W; Huang S; Wang Z; Zhao X; Du H; Song L; Peng X
Cell Tissue Res; 2014 Dec; 358(3):763-78. PubMed ID: 25296715
[TBL] [Abstract][Full Text] [Related]
15. E2F1 silencing inhibits migration and invasion of osteosarcoma cells via regulating DDR1 expression.
Wang Z; Sun X; Bao Y; Mo J; Du H; Hu J; Zhang X
Int J Oncol; 2017 Dec; 51(6):1639-1650. PubMed ID: 29039472
[TBL] [Abstract][Full Text] [Related]
16. Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer.
Wan Y; Zeng ZC; Xi M; Wan S; Hua W; Liu YL; Zhou YL; Luo HW; Jiang FN; Zhong WD
Hum Pathol; 2015 Feb; 46(2):295-303. PubMed ID: 25532941
[TBL] [Abstract][Full Text] [Related]
17. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
[TBL] [Abstract][Full Text] [Related]
18. A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis.
Kong LM; Liao CG; Zhang Y; Xu J; Li Y; Huang W; Zhang Y; Bian H; Chen ZN
Cancer Res; 2014 Jul; 74(14):3764-78. PubMed ID: 24906624
[TBL] [Abstract][Full Text] [Related]
19. NEDD9 crucially regulates TGF-β-triggered epithelial-mesenchymal transition and cell invasion in prostate cancer cells: involvement in cancer progressiveness.
Morimoto K; Tanaka T; Nitta Y; Ohnishi K; Kawashima H; Nakatani T
Prostate; 2014 Jun; 74(8):901-10. PubMed ID: 24728978
[TBL] [Abstract][Full Text] [Related]
20. Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.
Zhuo YJ; Liu ZZ; Wan S; Cai ZD; Xie JJ; Cai ZD; Song SD; Wan YP; Hua W; Zhong W; Wu CL
Biomed Pharmacother; 2018 Jun; 102():531-538. PubMed ID: 29587239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
